{"id":"NCT01543490","sponsor":"Sun Pharmaceutical Industries Limited","briefTitle":"Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-30","primaryCompletion":"2020-02-04","completion":"2020-02-04","firstPosted":"2012-03-05","resultsPosted":"2021-03-23","lastUpdate":"2021-11-19"},"enrollment":558,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Active, Symptomatic Blepharitis"],"interventions":[{"type":"DRUG","name":"ISV-305","otherNames":[]},{"type":"OTHER","name":"Vehicle","otherNames":[]}],"arms":[{"label":"ISV-305","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305 (Dexamethasone in DuraSiteÂ® 2) compared to Vehicle in the treatment of subjects with active, symptomatic Blepharitis.","primaryOutcome":{"measure":"Number of Participants in the ITT Population With a Reduction in the Day 1 (Baseline) Total Clinical Signs and Symptom Score by at Least 2 Units at Day 15 With No Worsening of Any Sign or Symptom","timeFrame":"Day 15","effectByArm":[{"arm":"ISV-305","deltaMin":276,"sd":null},{"arm":"Vehicle","deltaMin":129,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0354"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":367},"commonTop":["Conjunctival hyperaemia"]}}